Commodore Capital LP

Commodore Capital LP reported 37 holdings worth US$1.29B as of Sep 30, 2026 (Form 13F)

As of Sep 30, 2026 · Filed Nov 16, 2026

Commodore Capital LP reported 37 holdings worth US$1.29B as of Sep 30, 2026. Largest: Relay Therapeutics, Inc., Enliven Therapeutics, Inc. and Alto Neuroscience, Inc. Filed Nov 16, 2026 (Form 13F).

Holdings
37
Value as reported
US$1.29B

The filing in full

CompanySharesValue as reported% of portfolio
Relay Therapeutics, Inc.12MUS$217M16.8%
Enliven Therapeutics, Inc.3.27MUS$150M11.6%
Alto Neuroscience, Inc.2.72MUS$69.5M5.4%
Spyre Therapeutics, Inc.700KUS$62.3M4.8%
Amylyx Pharmaceuticals, Inc.2MUS$58.2M4.5%
LB Pharmaceuticals Inc1.28MUS$49.2M3.8%
Cogent Biosciences, Inc.1.26MUS$40.5M3.1%
Tyra Biosciences, Inc.1.73MUS$37.7M2.9%
Celldex Therapeutics, Inc.1MUS$32.4M2.5%
Surrozen, Inc.885KUS$28.5M2.2%
Sagimet Biosciences Inc. - Series A2.76MUS$27.2M2.1%
Definium Therapeutics, Inc.700KUS$26.6M2.1%
ADARx Pharmaceuticals, Inc.1.26MUS$25.1M1.9%
Editas Medicine, Inc.8.89MUS$22.8M1.8%
Attovia Therapeutics, Inc.1.16MUS$19.9M1.5%
Agenus Inc.1.99MUS$19.7M1.5%
Kymera Therapeutics, Inc.175KUS$19.6M1.5%
Avalo Therapeutics, Inc.1.02MUS$15.6M1.2%
AN2 Therapeutics, Inc.2.93MUS$15.6M1.2%
Century Therapeutics, Inc.8.7MUS$14.9M1.2%
Zura Bio Limited3.25MUS$13.5M1.0%
Inhibikase Therapeutics, Inc.5.4MUS$11.1M0.86%
Assembly Biosciences, Inc.462KUS$10.9M0.84%
PepGen Inc.4.47MUS$10.8M0.84%
SAB Biotherapeutics, Inc.2.87MUS$9.1M0.70%
Relmada Therapeutics, Inc.2.35MUS$8.86M0.69%
Research Alliance Corporation IV500KUS$5.79M0.45%
Helix Acquisition Corp. III500KUS$5.31M0.41%
JATT III Acquisition Corp400KUS$4.41M0.34%
TCGX Acquisition Corp.300KUS$3.75M0.29%
LeonaBio, Inc.464KUS$1.66M0.13%
Vistagen Therapeutics, Inc.0US$00.00%
Damora Therapeutics, Inc.0US$00.00%
EyePoint, Inc.0US$00.00%
Nuvalent, Inc.0US$00.00%
Perspective Therapeutics, Inc.0US$00.00%
Research Alliance Corporation III0US$00.00%
Tango Therapeutics, Inc.0US$00.00%

Source

Download original · View original at SEC

Related